-Phase III trial enrolled a total of 480 patients with moderate to severe acne-Topline results expected in the second quarter 2025 This Phase III clinical trial is a randomized, double-blind, ...
Acne is a concern for teens and adults alike, with many turning to over-the-counter or prescription remedies. However, there is one acne treatment that you should immediately stop using and toss in ...
Vietnam Investment Review on MSN
Ascletis ASC40 Phase III 2025 FASN Inhibitor Cuts Acne Lesions Fifty Per Cent
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the oral presentation of the Phase III study results of denifanstat (ASC40) for the treatment of moderate to severe acne vulgaris ...
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III clinical trial of ASC40 (denifanstat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback